Analysts See $-0.10 EPS for Sophiris Bio, Inc. (SPHS)

March 14, 2018 - By Vivian Currie

 Analysts See $ 0.10 EPS for Sophiris Bio, Inc. (SPHS)
Investors sentiment decreased to 0.64 in Q3 2017. Its down 1.96, from 2.6 in 2017Q2. It dived, as 6 investors sold Sophiris Bio, Inc. shares while 5 reduced holdings. 3 funds opened positions while 4 raised stakes. 1.63 million shares or 1.31% less from 1.65 million shares in 2017Q2 were reported.
Bancshares Of Ny Mellon Corp holds 0% or 17,500 shares. Blackrock reported 0% of its portfolio in Sophiris Bio, Inc. (NASDAQ:SPHS). Edge Wealth Management Limited Liability reported 0% stake. Morgan Stanley holds 0% in Sophiris Bio, Inc. (NASDAQ:SPHS) or 5,000 shares. Moreover, Palo Alto Ltd has 0.02% invested in Sophiris Bio, Inc. (NASDAQ:SPHS) for 247,000 shares. Citadel Advisors Limited Liability Corp invested in 36,721 shares. Jpmorgan Chase owns 22,011 shares. Guggenheim Limited Company has invested 0% of its portfolio in Sophiris Bio, Inc. (NASDAQ:SPHS). Bancshares Of Montreal Can reported 0% stake. Virtu Fincl Limited Liability Company has invested 0% in Sophiris Bio, Inc. (NASDAQ:SPHS). Lpl Fin Limited Liability Corp holds 0% or 10,000 shares in its portfolio. Wells Fargo Communication Mn has 1,800 shares for 0% of their portfolio. Royal State Bank Of Canada reported 0% stake. 3,338 were reported by Comml Bank Of America Corporation De. B T Mngmt Dba Alpha Mngmt stated it has 0.01% of its portfolio in Sophiris Bio, Inc. (NASDAQ:SPHS).

Analysts expect Sophiris Bio, Inc. (NASDAQ:SPHS) to report $-0.10 EPS on March, 26.They anticipate $0.03 EPS change or 42.86 % from last quarter’s $-0.07 EPS. After having $-0.11 EPS previously, Sophiris Bio, Inc.’s analysts see -9.09 % EPS growth. The stock decreased 1.87% or $0.04 during the last trading session, reaching $2.1. About 91,722 shares traded. Sophiris Bio, Inc. (NASDAQ:SPHS) has risen 192.94% since March 14, 2017 and is uptrending. It has outperformed by 176.24% the S&P500.

Sophiris Bio, Inc. (NASDAQ:SPHS) Ratings Coverage

Among 6 analysts covering Sophiris Bio (NASDAQ:SPHS), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Sophiris Bio had 11 analyst reports since August 30, 2016 according to SRatingsIntel. H.C. Wainwright maintained it with “Buy” rating and $6.0 target in Friday, September 15 report. H.C. Wainwright maintained Sophiris Bio, Inc. (NASDAQ:SPHS) rating on Friday, August 11. H.C. Wainwright has “Buy” rating and $600 target. The stock of Sophiris Bio, Inc. (NASDAQ:SPHS) earned “Buy” rating by H.C. Wainwright on Wednesday, January 17. On Monday, August 14 the stock rating was maintained by Maxim Group with “Buy”. The rating was initiated by Roth Capital on Thursday, September 15 with “Buy”. The firm has “Buy” rating given on Friday, June 9 by H.C. Wainwright. TH Capital initiated the stock with “Buy” rating in Thursday, September 15 report. The stock has “Overweight” rating by Piper Jaffray on Tuesday, August 30. Maxim Group maintained the shares of SPHS in report on Thursday, June 8 with “Buy” rating. The company was maintained on Friday, November 10 by H.C. Wainwright.

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company has market cap of $63.23 million. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia , as well as for the treatment of localized low to intermediate risk prostate cancer. It currently has negative earnings. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate.

More notable recent Sophiris Bio, Inc. (NASDAQ:SPHS) news were published by: which released: “Sophiris Bio Inc. SPHS (US: Nasdaq)” on August 10, 2013, also with their article: “Sophiris Bio Phase 3 BPH Study Successfully Meets Primary Endpoint” published on November 10, 2015, published: “Sophiris Bio Inc.” on November 10, 2015. More interesting news about Sophiris Bio, Inc. (NASDAQ:SPHS) were released by: and their article: “Sophiris Bio Announces that the First Patient Has Been Dosed in Phase 2b Study …” published on June 08, 2017 as well as‘s news article titled: “Sophiris Bio Reports Successful Results from Completed Phase 2a Study of …” with publication date: June 09, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: